8-K: PROCEPT BioRobotics Appoints Larry Wood as CEO Amid Strong Q2 Revenue Growth

PROCEPT BioRobotics announced the appointment of Larry L. Wood as its new President and CEO, effective September 2, 2025, succeeding retiring Dr. Reza Zadno, and pre-announced robust second-quarter 2025 revenue of approximately $79.2 million, marking a 48% annual increase.

Summary

• PROCEPT BioRobotics appointed Larry L. Wood as President and Chief Executive Officer, effective September 2, 2025.
• Mr. Wood will continue to serve as a Class I director on the Board of Directors.
• Current President and CEO, Dr. Reza Zadno, will step down from his roles and the Board on September 1, 2025, transitioning to a consulting role for up to 18 months.
• Dr. Zadno's departure is not the result of any disagreement with the company.
• The company pre-announced estimated revenue for the quarter ended June 30, 2025, of approximately $79.2 million, representing an annual growth of 48%.
• Mr. Wood's compensation package includes an initial base salary of $925,000, a target annual bonus opportunity of 100% of base salary (pro-rated for 2025), and a sign-on bonus of $1,700,000.
• Mr. Wood will also receive equity awards with target grant values of approximately $7,500,000 in Buy-Out Restricted Stock Units, $7,500,000 in New-Hire Stock Options, and $3,000,000 in New-Hire Performance Stock Units.
• Dr. Zadno will receive severance benefits including a lump sum payment of $708,000 (12 months of base salary), a pro-rated target bonus for 2025 of $472,000, and COBRA continuation for up to 12 months.
• Dr. Zadno's outstanding equity awards will continue to vest during his consulting period, and his 2025 equity awards will be subject to accelerated vesting in accordance with qualifying retirement terms.

Sentiment

Score: 8

Explanation: The filing announces strong revenue growth and a well-managed CEO transition with an experienced successor, indicating positive momentum and strategic stability.

Positives

• Strong estimated revenue growth of 48% year-over-year for Q2 2025, reaching approximately $79.2 million, indicating robust business performance.
• Appointment of Larry L. Wood, an executive with over 40 years of extensive experience in the medical technology industry, including leadership roles at Edwards Lifesciences, brings significant expertise.
• Mr. Wood has prior experience with the company, having served on its Board of Directors since April 2024, suggesting a smooth and informed leadership transition.
• The CEO transition is described as a 'coordinated succession search process' and Dr. Zadno's departure is not due to any disagreement, indicating organizational stability.
• Dr. Zadno will transition to a consulting role for up to 18 months, ensuring continued advisory support during the leadership change.

Negatives

• The departure of Dr. Reza Zadno, who led the company through significant growth and commercial expansion, could introduce a period of adjustment.
• The substantial compensation package for the new CEO, including a $1.7 million sign-on bonus and $18 million in equity awards, represents a significant financial commitment.

Risks

• Forward-looking statements, including projected financial performance, market opportunity, clinical trial outcomes, and future results of operations, involve risks and uncertainties that could cause actual results to differ materially from anticipated results.
• Risks and uncertainties are described more fully in the company's SEC filings, including its annual report on Form 10-K and subsequent quarterly reports on Form 10-Q.

Future Outlook

The company's forward-looking statements include expectations regarding its projected financial performance for full year 2025, the potential utilities, values, benefits, and advantages of its Aquablation therapy using AQUABEAM and HYDROS Robotic Systems, and future clinical trial outcomes. These also encompass possible future results of operations, including revenues, gross margins, profitability, operating expenses, installed base growth, commercial momentum, and overall business strategy.

Management Comments

• "On behalf of the board of directors, I want to thank Reza for his dedication to the Company and its mission over the past five years. Reza's deep understanding of the potential of the Company's novel technology to redefine the standard of care for BPH and steadfast leadership through key milestones have paved the way for even greater growth and opportunity ahead." Thomas M. Prescott, PROCEPT BioRobotics chairperson.
• "The last five years have been among the most rewarding of my career and I am very proud of what our team has achieved. We grew the number of global Aquablation procedures from a few hundred to nearly one hundred thousand, raised more than $600M capital to support our continued growth, significantly increased enterprise value, and most importantly, we have changed the treatment landscape for patients suffering from BPH and the doctors who treat them. We are just scratching the surface of what's possible, and I am thrilled to pass the torch to Larry Wood to lead the next phases of the Company's exciting journey." Dr. Reza Zadno, PROCEPT BioRobotics president and CEO.
• "Larry's strengths and vast experience in the medical technology industry are a great fit with the opportunities ahead for PROCEPT BioRobotics. Larry has demonstrated outstanding leadership and business acumen in one of the most clinically demanding medical device product categories and is known for championing technologies that can significantly benefit patients. At Edwards, Larry and his team revolutionized how patients with severe aortic stenosis are treated. We are excited to have Larry join the Company as CEO, especially after having the opportunity to get to know him, his leadership style, and his insights during his tenure on the PROCEPT BioRobotics board." Mr. Prescott.
• "I am honored to join PROCEPT BioRobotics at such a pivotal time in the Company's growth. The Company's innovative approach to treating prostate disorders has the potential to transform the standard of care for patients worldwide. I look forward to leading this exceptional team and building on their many successes to continue to improve treatment outcomes for doctors and their patients." Mr. Wood.

Industry Context

PROCEPT BioRobotics operates in the surgical robotics and urology medical technology sector, specifically focusing on Benign Prostatic Hyperplasia (BPH) treatment with its Aquablation therapy. The appointment of Larry L. Wood, a veteran from Edwards Lifesciences, a global leader in structural heart disease and critical care, signals a strategic move to leverage deep medical device industry experience. This aligns with a broader industry trend of bringing seasoned leadership from established medical device giants into growing specialized segments like surgical robotics to drive commercialization and market penetration. The company's focus on BPH, a common prostate disease affecting approximately 40 million men in the U.S., positions it within a significant and growing market for minimally invasive urological procedures.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• NA

Stakeholder Impact

• Shareholders: Positive impact due to strong revenue growth and the appointment of an experienced CEO, potentially leading to increased share price and long-term value.
• Employees: Potential for new strategic direction under new leadership; continuity provided by Dr. Zadno's consulting role.
• Customers (Urologists): Continued focus on advancing BPH treatment with robotic solutions, potentially leading to further innovation and support for Aquablation therapy.
• Patients: Continued development and adoption of Aquablation therapy aims to improve treatment outcomes for males suffering from BPH.

Next Steps

• PROCEPT BioRobotics will report second quarter 2025 earnings results after market close on Wednesday, August 6, 2025.
• The company's management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time on August 6, 2025.
• New-hire performance stock units for Mr. Wood are intended to be granted in the first quarter of calendar year 2026.

Key Dates

Recommendation

The filing indicates robust financial performance with a 48% year-over-year revenue growth, signaling strong market adoption and operational execution. The appointment of Larry L. Wood, a highly experienced and respected leader from Edwards Lifesciences, ensures continuity and brings deep industry expertise to guide future growth. The smooth transition, with the outgoing CEO moving into a consulting role, minimizes disruption. These factors collectively point to a positive outlook and strong potential for continued value creation.

Keywords

Surgical Robotics, Urology, BPH Treatment, Aquablation Therapy, Medical Technology, CEO Appointment, Executive Transition, Financial Results, Revenue Growth, PROCEPT BioRobotics, PRCT, Edwards Lifesciences, Baxter Healthcare